La catena delle opzioni mostra i dati chiave delle opzioni azionarie di Orchestra BioMed Hldgs a vari prezzi di esercizio e date di scadenza. I trader utilizzano queste informazioni per analizzare potenziali operazioni e valutare il sentiment del mercato per Orchestra BioMed Hldgs..

Orchestra BioMed Hldgs (NASDAQ:OBIO) Azioni, Catena delle Opzioni

ORCHESTRA BIOMED HOLDINGS IN

Orchestra BioMed Hldgs

Orchestra BioMed Holdings Inc is a biomedical innovation company accelerating high-impact technologies to patients through risk-reward sharing partnerships. Its partnership-enabled business model focuses on forging strategic collaborations with medical device companies to drive the commercialization of the products it develops. The company's flagship product candidates include BackBeat Cardiac Neuromodulation Therapy (CNT) for the treatment of hypertension and Virtue Sirolimus AngioInfusionBalloon (SAB) for the treatment of atherosclerotic artery disease.

U.S. stocks traded mixed this morning, with the Dow Jones index falling around 100 points on Tuesday.
Following the market opening Tuesday, the Dow traded down 0.22% to 44,309.37 while the NASDAQ gained 0.07% to 20,426.62. The S&amp;P 500 also fell, dropping, 0.06% to 6,226.07.
Check This Out: <a href="https://www.benzinga.com/trading-ideas/short-ideas/25/07/46296650/top-2-industrials-stocks-you-may-want-to-dump-this-quarter">Top 2 Industrials Stocks You May Want To Dump This Quarter</a>
Leading and Lagging Sectors Energy shares jumped by 1% on Tuesday.
In trading on Tuesday, utilities stocks dipped by 1.5%.
Top Headline
The NFIB Small Business Optimism Index fell to 98.6 in June from 98.8 in May and compared to market estimates of 98.7.
Equities Trading UP &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<ul class="wp-block-list">
<li>ENDRA Life Sciences Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NDRA#NASDAQ">NDRA</a>) shares shot up 159% to $8.95 after the company announced it will be granted a US patent titled &#8220;Radio Frequency Applicator&#8221;.</li>
<li>Shares of ProKidney Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PROK#NASDAQ">PROK</a>) got a boost, surging 113% to $1.2911 after the company reported statistically and clinically significant topline results from its Phase 2 REGEN-007 trial evaluating Rilparencel in patients with chronic kidney disease and diabetes.</li>
<li>Bolt Projects Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BSLK#NASDAQ">BSLK</a>) shares were also up, gaining 64% to $4.17.</li>
</ul>
Equities Trading DOWN
<ul class="wp-block-list">
<li>Skyline Builders Group Holding Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SKBL#NASDAQ">SKBL</a>) shares dropped 28% to $1.1053.</li>
<li>Shares of MaxsMaking Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MAMK#NASDAQ">MAMK</a>) were down 26% to $2.7387</li>
<li>Above Food Ingredients Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ABVE#NASDAQ">ABVE</a>) was down, falling 25% to $0.5101. Above Food announced merged with Palm Global.</li>
</ul>
Commodities In commodity news, oil traded down 0.3% to $67.75 while gold traded down 0.6% at $3,323.90.
Silver traded down 0.5% to $36.735 on Tuesday, while copper fell 0.6% to $4.9965.
Euro zone
European shares were higher today. The eurozone's STOXX 600 rose 0.2%, while Spain's IBEX 35 Index rose 0.1%. London's FTSE 100 gained 0.4%, Germany's DAX 40 gained 0.6% and France's CAC 40 gained 0.3% during the session.
Asia Pacific Markets
Asian markets closed higher on Tuesday, with Japan's Nikkei gaining 0.26%, Hong Kong's Hang Seng climbing 1.09%, China's Shanghai Composite gaining 0.70% and India's BSE Sensex gaining 0.32%.
Economics
<ul class="wp-block-list">
<li>The US Manheim Used Vehicle Value Index increased 1.6% month-over-month for June, following a 1.4% decline in May.</li>
<li>The NFIB Small Business Optimism Index fell to 98.6 in June from 98.8 in May and compared to market estimates of 98.7.</li>
</ul>
Now Read This: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/news/25/07/46296955/meta-platforms-to-rally-around-9-here-are-10-top-analyst-forecasts-for-tuesday">Meta Platforms To Rally Around 9%? Here Are 10 Top Analyst Forecasts For Tuesday</a></li>
</ul>
Photo via Shutterstock

Equities

News

Eurozone

Commodities

Intraday Update

Markets

ABVE

BSLK

MAMK

NDRA

PROK

SKBL

US Stocks Mixed; Small Business Sentiment Falls In June

A million used to be the magic number for retirement. Then inflation, <a href="https://www.benzinga.com/personal-finance/25/01/43034131/global-lifespans-are-rising-should-your-retirement-age-rise-too-what-it-means-for-workers-in-the-u-s-and-beyond">longer lifespans</a>, and rising healthcare costs moved the goalposts. These days, plenty of people are <a href="https://www.benzinga.com/25/03/44257254/can-you-guess-how-many-people-really-retire-with-a-2-million-nest-egg-heres-a-hint-its-a-super-low-number">aiming for $2 million</a> — or even $2.5 million — just to feel secure. But while that might seem like the new benchmark, the reality is that very few people actually reach it.
According to the <a href="https://www.ebri.org/docs/default-source/ebri-press-release/pr-1363-spendingspikes-5sept24.pdf?sfvrsn=f3d5072f_1">Employee Benefit Research Institute's analysis</a> of Federal Reserve data, just 1.8% of U.S. households have at least $2 million in retirement savings. And when you push that to $2.5 million, the number shrinks even further — somewhere between the 1.8% with $2 million and the 0.8% with $3 million.
In other words, if you're chasing $2.5 million, you're entering rare territory.
Don't Miss:
<ul class="wp-block-list">
<li>Warren Buffett once said, "If you don't find a way to make money while you sleep, you will work until you die."<a href="https://www.benzinga.com/money/warren-buffet-make-money-when-you-sleep"> Here&#8217;s how you can earn passive income with just $10.</a></li>
<li>$100k+ in investable assets? <a href="https://www.benzinga.com/money/wiseradvisor-retirement-planning">Match with a fiduciary advisor for free to learn how you can maximize your retirement and save on taxes</a> – no cost, no obligation.</li>
</ul>
For context, the median retirement savings across all households is $87,000. The average is about $333,940, skewed higher by wealthier households. Even among retirees aged 65 and up, the average balance is just $573,624 — and the median is still far below seven figures.
So why is $2.5 million such a tough milestone to hit?
It's not just about financial literacy or discipline. Hitting that number usually requires starting early, saving consistently, and investing aggressively for decades — all while earning enough to cover rising living costs. That kind of financial runway isn't available to most Americans.
Still, what does $2.5 million really mean for your retirement?
Quite a bit, actually. Using the common 4% rule, $2.5 million could generate $100,000 per year — not including Social Security or other income. That's enough to cover a comfortable lifestyle in most of the U.S., even with room for healthcare, housing, and the occasional splurge.
Trending: The secret weapon in billionaire investor portfolios that you almost certainly don't own yet. <a href="https://www.benzinga.com/money/masterworks">See which asset class has outpaced the S&amp;P 500 (1995-2024) – and with near-zero correlation.</a>
It also puts you in an elite group. While the number might not feel extravagant in 2025 terms, the truth is very few retirees reach it — and those who do sit well inside the top 2% of retirement savers.
If you're retiring at 65 and plan to live another 25 to 30 years, $2.5 million can stretch far — but only if you manage it carefully. At $100,000 per year, you're right on pace with the 4% rule. Add in Social Security — which <a href="https://www.ssa.gov/faqs/en/questions/KA-01903.html">averages around $1,900 per month</a> or roughly $23,000 annually — and you're looking at over $120,000 in income. That's more than enough to cover essentials and extras in most areas, even factoring in healthcare and inflation.
Now, if you retire earlier — say, at 62 — the math gets trickier. You'll need to stretch that money over more years, and you may receive reduced Social Security benefits. For early retirees, $2.5 million might need to last 30 to 35 years. That lowers the safe withdrawal rate closer to 3.5% or less, meaning your annual draw would be closer to $87,500 to avoid running out too soon.
And then there's inflation. Over the last 30 years, <a href="https://www.usinflationcalculator.com/inflation/current-inflation-rates/">inflation has averaged just over 2.5%</a> annually. But in recent years, it's been higher. That means today's $100,000 might not buy the same lifestyle 20 years from now — which is why many retirees invest a portion of their portfolio for growth even after they stop working.
See Also: <a href="https://www.benzinga.com/money/gbr-savings-by-age">If You're Age 35, 50, or 60: Here&#8217;s How Much You Should Have Saved Vs. Invested By Now</a>
The upside? With $2.5 million, you have options. You can travel. You can move to a lower-cost area. You can handle unexpected bills without panic. But it takes planning — and getting there in the first place is the biggest hurdle.
If you're already there — or even beyond it — that's something to be proud of. It usually takes years of focus, patience, and consistent effort to reach that point.&nbsp;
But if you're not quite there yet, that doesn't mean you're off track. Everyone's retirement number is different, and $2.5 million might not even be your goal. What matters is having a plan — saving steadily, investing wisely, and adjusting along the way. And if you're unsure what your target should be or how close you are, it's worth <a href="https://www.benzinga.com/money/are-you-rich">checking in with a financial advisor</a> who can help tailor a strategy that actually fits your life.
Read Next: Over the last five years, the price of gold has increased by approximately 83% — Investors like Bill O&#8217;Reilly and Rudy Giuliani are using this platform to <a href="https://www.benzinga.com/money/american-hartford-gold">create customized gold IRAs to help shield their savings from inflation and economic turbulence.&nbsp;</a>
Image: Shutterstock

Personal Finance

Who Actually Retires With $2.5 Million? The Number Is Shockingly Small — Are You On Track Or Falling Behind?

Mizuho analyst Vijay Rakesh maintains Mobileye Global (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MBLY#NASDAQ">MBLY</a>) with a Neutral and raises the price target from $15 to $18.

Price Target

Analyst Ratings

MBLY

Mizuho Maintains Neutral on Mobileye Global, Raises Price Target to $18

Honeywell International Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HON#NASDAQ">HON</a>) announced Monday that it is <a target="_blank" href="https://www.benzinga.com/pressreleases/25/07/n46291891/honeywell-to-evaluate-strategic-alternatives-for-productivity-solutions-and-services-and-warehouse" rel="noreferrer noopener">weighing strategic options</a> for two of its logistics-focused business units, part of an ongoing restructuring designed to streamline operations ahead of a major corporate split slated for 2026.
Honeywell is exploring potential paths for its Productivity Solutions and Services (PSS) and Warehouse and Workflow Solutions (WWS) units, both of which cater to the transportation and logistics sectors. These deliberations come as the company positions itself to emerge as a dedicated automation player following the planned separation of its aerospace and materials divisions.
Vimal Kapur, Chairman and CEO of the company, said the move aligns with Honeywell&#8217;s goal of sharpening its focus on industrial, process, and building automation. Once the spin-offs are complete, Honeywell aims to concentrate exclusively on markets with robust long-term growth prospects.
Also Read: <a href="https://www.benzinga.com/trading-ideas/technicals/25/06/46057818/golden-cross-alert-honeywell-nears-a-bullish-breakout-as-strategic-shakeup-gains-traction" target="_blank" rel="noreferrer noopener">Golden Cross Alert: Honeywell Nears A Bullish Breakout As Strategic Shakeup Gains Traction</a>
PSS, which brought in more than $1 billion in revenue last year, provides mobile computing and barcode solutions for warehouses. WWS, which operates under the Intelligrated and Transnorm brands, generated nearly $1 billion in 2024 through supply chain automation tools such as sortation systems, robotics, and conveyor systems. Both units boast established customer bases and wide-ranging product portfolios.
Although the company hasn&#8217;t committed to a specific outcome, the review process will run concurrently with Honeywell&#8217;s broader corporate reshaping. It won&#8217;t impact existing plans to <a target="_blank" href="https://www.benzinga.com/news/asset-sales/24/12/42505835/honeywell-advances-strategic-review-explores-aerospace-business-separation" rel="noreferrer noopener">spin off</a> the Solstice Advanced Materials business by early 2026 and the aerospace division in the second half of the same year.
As part of the restructuring, Honeywell also appointed Jim Masso to lead its process automation division, effective July 14. Masso, a seasoned executive with two decades of experience across energy and industrial sectors, most recently served as CEO of Allied Power Group and held key leadership roles at General Electric Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GE#NYSE">GE</a>).
Related ETFs: Industrial Select Sector SPDR Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLI#NYSE">XLI</a>), Vanguard Industrials ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VIS#NYSE">VIS</a>).
Price Action: HON shares are trading higher by 0.39% to $240.29 premarket at last check Tuesday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/equities/25/07/46267993/lockheed-martin-tops-defense-peers-in-capital-efficiency-but-market-isnt-impressed" target="_blank" rel="noreferrer noopener">Lockheed Martin Tops Defense Peers In Capital Efficiency — But Market Isn&#8217;t Impressed</a></li>
</ul>
Photo by Piotr Swat via Shutterstock

Asset Sales

Honeywell Eyes Strategic Changes Ahead Of 2026 Split

BlackRock (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BLK#NYSE">BLK</a>) has outperformed the market over the past 15 years by 1.53% on an annualized basis producing an average annual return of 13.79%. Currently, BlackRock has a market capitalization of $167.17 billion. 
Buying $1000 In BLK: If an investor had bought $1000 of BLK stock 15 years ago, it would be worth $6,866.38 today based on a price of $1079.00 for BLK at the time of writing.
<h3>BlackRock's Performance Over Last 15 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1751984113_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Trading Ideas

$1000 Invested In BlackRock 15 Years Ago Would Be Worth This Much Today

JMP Securities analyst Jason Butler reiterates Rapport Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RAPP#NASDAQ">RAPP</a>) with a Market Outperform and maintains $28 price target.

Reiteration

RAPP

JMP Securities Reiterates Market Outperform on Rapport Therapeutics, Maintains $28 Price Target

<a href="https://www.bloomberg.com/news/articles/2025-07-08/us-acts-against-foreign-ownership-of-farmland-amid-china-tension?embedded-checkout=true">https://www.bloomberg.com/news/articles/2025-07-08/us-acts-against-foreign-ownership-of-farmland-amid-china-tension?embedded-checkout=true</a>

General

'US Acts Against Foreign Ownership of Farmland Amid China Tension'- Bloomberg

Mizuho analyst Vijay Rakesh maintains Microchip Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MCHP#NASDAQ">MCHP</a>) with a Outperform and raises the price target from $78 to $85.

MCHP

Mizuho Maintains Outperform on Microchip Technology, Raises Price Target to $85

JMP Securities analyst Jonathan Wolleben maintains KalVista Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KALV#NASDAQ">KALV</a>) with a Market Outperform and raises the price target from $19 to $27.

KALV

JMP Securities Maintains Market Outperform on KalVista Pharma, Raises Price Target to $27

WIIM

CRWV

CoreWeave shares are trading lower after Mizuho downgraded the stock from Outperform to Neutral. Yesterday, the stock fell following an announcement that it will acquire Core Scientific.

Mizuho analyst Vijay Rakesh maintains Allegro Microsystems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALGM#NASDAQ">ALGM</a>) with a Outperform and raises the price target from $31 to $37.

ALGM

Mizuho Maintains Outperform on Allegro Microsystems, Raises Price Target to $37

JMP Securities analyst Silvan Tuerkcan maintains Jasper Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JSPR#NASDAQ">JSPR</a>) with a Market Outperform and lowers the price target from $70 to $12.

Jasper Therapeutics, Inc. - Class A Common Stock

JSPR

JMP Securities Maintains Market Outperform on Jasper Therapeutics, Lowers Price Target to $12

DDOG

Datadog shares are trading lower after Guggenheim downgraded the stock from Neutral to Sell and announced a $105 price target.

Mizuho analyst Brett Linzey initiates coverage on AIRO Group Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AIRO#NASDAQ">AIRO</a>) with a Outperform rating and announces Price Target of $31.

Initiation

AIRO

Mizuho Initiates Coverage On AIRO Group Holdings with Outperform Rating, Announces Price Target of $31

Scotiabank analyst Nat Schindler initiates coverage on AppLovin (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APP#NASDAQ">APP</a>) with a Sector Outperform rating and announces Price Target of $430.

Scotiabank Initiates Coverage On AppLovin with Sector Outperform Rating, Announces Price Target of $430

Parrot Uncle is a World Leading Ceiling Fan and Home Décor Manufacturer Selling Millions of Ceiling Fans in the U.S. and Global Markets
Ceiling Fans and Space Heaters Category Represents a Multi-Billion-Dollar Annual Market with Tens of Millions of Units Sold in the U.S. Alone
SKYX Anticipates Q3 Winter Global Launch Will Support its Path to Cash-Flow Positive in 2025
MIAMI, July 08, 2025 (GLOBE NEWSWIRE) -- SKYX Platforms Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SKYX#NASDAQ">SKYX</a>) ("SKYX" or the "Company"), a highly disruptive smart home platform technology company with over 100 issued and pending patents globally and a growing portfolio of over 60 lighting and home décor websites, with a mission to make homes and buildings become smart, safe, and advanced as the new standard, today announced a U.S. and global sales and marketing collaboration agreement with Parrot Uncle, a world leading ceiling fan and home décor manufacturer selling millions of fans globally.
SKYX and Parrot Uncle will jointly market SKYX's disruptive technologies and products in the U.S. and to global markets including its patented all-in-one smart turbo heater &amp; ceiling fan.
The ceiling fan and space heater category represents a multi-billion-dollar annual market with tens of millions of units sold in the U.S. alone.
In response to the strong demand, SKYX will introduce two different versions of the product each in 6 to 8 colors, designed to meet both residential and commercial needs. Production has officially begun with the Company's manufacturing partners, and SKYX anticipates a broad launch in Q3 2025, aligned with the upcoming winter season.
This highly innovative product—integrating a ceiling fan with a built-in heater—is designed to address a massive market opportunity for all four seasons. The combined ceiling fan and portable heater category is a multi-billion-dollar market, with tens of millions of units sold annually in the U.S. alone.
The Company believes that the successful launch of this product line is a critical milestone on its path toward achieving cash-flow positive operations in 2025.

SKYX

SKYX  Announces A U.S. And Global Sales And Marketing Collaboration Agreement With Parrot Uncle To Launch Smart Ceiling Fan & Heater Globally In Q3 2025

Mizuho analyst Gregg Moskowitz downgrades CoreWeave (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRWV#NASDAQ">CRWV</a>) from Outperform to Neutral and raises the price target from $70 to $150.

Downgrades

Mizuho Downgrades CoreWeave to Neutral, Raises Price Target to $150

Cantor Fitzgerald analyst Colin Canfield initiates coverage on Kratos Defense &amp; Security (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KTOS#NASDAQ">KTOS</a>) with a Overweight rating and announces Price Target of $60.

KTOS

Cantor Fitzgerald Initiates Coverage On Kratos Defense & Security with Overweight Rating, Announces Price Target of $60

OSR Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OSRH#NASDAQ">OSRH</a>), a global healthcare company advancing biomedical and wellness innovation, today announced the official roadmap for a targeted $50 million security token offering (STO) planned for launch in the second half of 2025 under Regulation D of the U.S. Securities Act. The token, with the working title OSRT, will be a securitized digital asset representing OSR Holdings' equity exposure and is designed to align with the company's blockchain-based capital strategy.
As part of this roadmap, Taekwondo Access Credit (TAC)—a utility token that rewards participation and has growing adoption in the global Taekwondo community —will be accepted alongside Bitcoin (BTC) and Tether (USDT) as eligible currencies for subscription to the OSRT offering. Taekwondo remains one of the world's most widely practiced martial arts, with an estimated 70 million practitioners of all ages across 190 countries.
BCM Europe intends to convert a substantial portion of its TAC holdings into BTC or USDT through market-based transactions prior to its anticipated participation. Due to the convertibility of TAC into OSRT and to ensure compliance and mitigate potential insider trading concerns, BCM Europe AG, the issuer of TAC and the largest shareholder of OSR Holdings, will not be permitted to use TAC directly in subscribing to the OSRT offering. Other interested and eligible subscribers of OSRT will be able to use BTC, USDT, or TAC to acquire OSRT tokens.
"Our upcoming STO is not just a tokenization of our equity – it's a foundational element of our long-term capital and treasury strategy," said Peter Hwang, CEO of OSR Holdings. "We believe that our combined $50 million STO plan and $80 million equity line of credit (ELOC) from White Lion GBM Innovation Fund provides a credible and achievable path towards building a $100 million Bitcoin and USDT reserve on our balance sheet."
Key Elements of the&nbsp;OSRT Security Token Roadmap:
<ul>
<li>Plan for up to $50 Million STO Under Reg D: OSR Holdings aims to raise up to $50 million in digital assets via the OSRT token in the second half of 2025, offered under Regulation D, targeting accredited investors.</li>
<li>Eligibility of BTC, USDT, and TAC: OSRT will be offered to accredited investors who may subscribe using BTC, USDT, or TAC, enabling diversified participation and aligning with OSRH's existing blockchain ecosystem partnerships.</li>
<li>Special Restrictions for BCM Europe AG: While TAC will be accepted from eligible investors in the STO, BCM Europe AG, as the issuer of TAC and a major shareholder of OSR Holdings, will not be permitted to subscribe using TAC directly. Instead, BCM Europe will convert its TAC holdings into BTC or USDT through market-based transactions, a process designed to avoid conflicts of interest and align with best practices on insider participation.</li>
<li>ELOC-Backed Liquidity Plan: In parallel to the STO, OSR Holdings continues to draw from its $80 million ELOC from White Lion GBM Innovation Fund, further reinforcing its capital base and enabling the company to scale its crypto holdings toward a realistic $100 million reserve.</li>
<li>Crypto-Healthcare Convergence Strategy: OSRH is integrating decentralized finance with healthcare innovation, supported by its unique ecosystem that includes TAC, which is already actively used within the global Taekwondo community. Additional announcements on TAC real-world integration with digital healthcare are planned for 3Q2025.</li>
</ul>

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

OSRH

OSR Holdings Unveils $50M Security Token Offering Roadmap For OSRT Token Launch In H2 2025, Accepting BTC, USDT, And Taekwondo Access Credit As Subscription Currencies

Mizuho analyst John Baumgartner initiates coverage on Vital Farms (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VITL#NASDAQ">VITL</a>) with a Outperform rating and announces Price Target of $45.

VITL

Mizuho Initiates Coverage On Vital Farms with Outperform Rating, Announces Price Target of $45

Health Care

Press Releases

Orchestra BioMed Receives FDA Breakthrough Device Designation for AVIM Therapy

Vivasure Medical Receives CE Mark Approval in Europe for PerQseal Elite Vascular Closure System

SmallCaps Gaining Momentum: TIVC, GELS, SLI, OBIO in Healthcare, Biotech, Energy, Military Defense, Etc. – More Stocks Inside

Orchestra BioMed Announces AVIM Therapy-Focused Satellite Symposium at HRS 2025 Annual Meeting

Orchestra BioMed to Participate in Upcoming Institutional Investor Conferences

Orchestra BioMed Receives FDA Approval of IDE to Initiate U.S. Coronary Pivotal Trial Randomizing First-in-Class Sirolimus-AngioInfusion Balloon, Virtue SAB, Head-to-Head with Paclitaxel-Coated Balloon

Comments

Orchestra BioMed Hldgs

Orchestra BioMed Hldgs (OBIO) Opzioni

No option chain data available. Please try again later

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO